<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03865407</url>
  </required_header>
  <id_info>
    <org_study_id>HM20014698</org_study_id>
    <nct_id>NCT03865407</nct_id>
  </id_info>
  <brief_title>Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease</brief_title>
  <official_title>Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim 1. To determine the effect of Allopurinol treatment on renal function (glomerular&#xD;
      filtration rate, GFR) in pediatric chronic kidney disease (CKD) patients with high uric acid&#xD;
      levels (hyperuricemia).&#xD;
&#xD;
      Aim 2. Establish whether Allopurinol treatment reduces Nlrp3 inflammasome and renal injury&#xD;
      biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uric acid levels often rise when kidney function declines. Historically, high uric acid has&#xD;
      not been treated unless the uric acid crystallizes in the joint space and causes clinical&#xD;
      gout disease, more typically seen in adults. However, new research has shown that high uric&#xD;
      acid levels are associated with the development of hypertension, inflammation, and both acute&#xD;
      and chronic kidney injury. Adult patients on renal dialysis who have hyperuricemia also have&#xD;
      higher mortality rates. In several adult and in one pediatric clinical trial of uric acid&#xD;
      lowering therapy (with Allopurinol or Febuxostat), treatment has demonstrated a slower rate&#xD;
      of renal function decline and improved blood pressure compared to placebo. The pediatric&#xD;
      trial was a 4-month placebo controlled trial of Allopurinol, and showed positive improvement&#xD;
      in renal function and blood pressure, but did not adequately control for potential&#xD;
      confounders in the outcome. Two known confounders that influence renal function (glomerular&#xD;
      filitration rate, GFR) in pediatric CKD are race and glomerular or non-glomerular disease&#xD;
      etiology. This study is designed to control for these confounders and establish whether&#xD;
      Allopurinol for 6 months of treatment to a goal range of 3-5 mg/dL will improve renal&#xD;
      function compared to standard of care. The secondary outcome is to determine whether blood&#xD;
      pressure is affected by the treatment and the magnitude of change of serum uric acid. This&#xD;
      study will also explore whether Allopurinol treatment alters activation of the Nlrp3&#xD;
      inflammasome or renal injury biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    inability to achieve recruitment goals at a single center and given the current pandemic&#xD;
    conditions&#xD;
  </why_stopped>
  <start_date type="Actual">March 10, 2019</start_date>
  <completion_date type="Actual">October 7, 2020</completion_date>
  <primary_completion_date type="Actual">October 7, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>eGFR Change</measure>
    <time_frame>The difference in Cystatin C eGFR between baseline and 6 months will be measured</time_frame>
    <description>Change in Cys-C eGFR over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>eGFR Change</measure>
    <time_frame>The difference in Creatinine eGFR between baseline and 6 months will be measured</time_frame>
    <description>Change in Creatinine eGFR over time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Uric Acid Change</measure>
    <time_frame>The difference in Serum Uric Acid between baseline and 6 months will be measured</time_frame>
    <description>Change in Serum Uric Acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>The difference in clinic systolic blood pressure between baseline and 6 months will be measured</time_frame>
    <description>Change in systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>The difference in clinic diastolic blood pressure between baseline and 6 months will be measured</time_frame>
    <description>Change in diastolic blood pressure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum High Sensitivity C-reactive Protein (Hs-CRP)</measure>
    <time_frame>Serum hs-CRP will be measured at baseline and 6 months</time_frame>
    <description>Compare the mean difference of serum hs-CRP from baseline to 6 months between groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Interleukin 18</measure>
    <time_frame>Serum interleukin 18 will be measured at baseline, 3 months, and 6 months</time_frame>
    <description>Change in interleukin 18</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Nlrp3</measure>
    <time_frame>Serum Nlrp3 will be measured at baseline, 3 months, and 6 months</time_frame>
    <description>Change in serum Nlrp3</description>
  </other_outcome>
  <other_outcome>
    <measure>Urine Neutrophil Gelatinase-associated Lipocalin (NGAL)</measure>
    <time_frame>Urine NGAL will be measured at baseline, 3 months, and 6 months</time_frame>
    <description>Change in urine NGAL</description>
  </other_outcome>
  <other_outcome>
    <measure>Urine Endothelin-1 (ET-1)</measure>
    <time_frame>Urine ET-1 will be measured at baseline, 3 months, and 6 months</time_frame>
    <description>Change in urine ET-1</description>
  </other_outcome>
  <other_outcome>
    <measure>Urine Kidney Injury Molecule-1 (KIM-1)</measure>
    <time_frame>Urine KIM-1 will be measured at baseline, 3 months, and 6 months</time_frame>
    <description>Change in urine KIM-1</description>
  </other_outcome>
  <other_outcome>
    <measure>Urine N-acetyl-Beta-D-Glucosaminidase (NAG)</measure>
    <time_frame>Urine NAG will be measured at baseline, 3 months, and 6 months</time_frame>
    <description>Change in urine NAG</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Hyperuricemia</condition>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The treatment arm will be compared to a standard of care arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Allopurinol dosed to target uric acid levels of 3-5 mg/dL.</description>
    <arm_group_label>Allopurinol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic Kidney Disease stage 1-5&#xD;
&#xD;
          -  Hyperuricemic (UA &gt;= 5.5 mg/dL)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to Allopurinol&#xD;
&#xD;
          -  Elevated baseline liver function tests&#xD;
&#xD;
          -  Receiving acute or chronic dialysis&#xD;
&#xD;
          -  Primary metabolic disorder&#xD;
&#xD;
          -  Sickle cell disease&#xD;
&#xD;
          -  Autosomal Dominant Polycystic Kidney Disease&#xD;
&#xD;
          -  Cystinosis&#xD;
&#xD;
          -  Bartter or Gitelman Disease&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristin Kaspar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <results_first_submitted>May 4, 2021</results_first_submitted>
  <results_first_submitted_qc>May 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 27, 2021</results_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT03865407/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Allopurinol</title>
          <description>Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.&#xD;
Allopurinol: Allopurinol dosed to target uric acid levels of 3-5 mg/dL.</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care Control</title>
          <description>The treatment arm will be compared to a standard of care arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medical change caused patient to no longer meet inclusion/exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Allopurinol</title>
          <description>Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.&#xD;
Allopurinol: Allopurinol dosed to target uric acid levels of 3-5 mg/dL.</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care Control</title>
          <description>The treatment arm will be compared to a standard of care arm.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.29" spread="2.5"/>
                    <measurement group_id="B2" value="13.86" spread="2.61"/>
                    <measurement group_id="B3" value="14.07" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>eGFR Change</title>
        <description>Change in Cys-C eGFR over time</description>
        <time_frame>The difference in Cystatin C eGFR between baseline and 6 months will be measured</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol</title>
            <description>Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.&#xD;
Allopurinol: Allopurinol dosed to target uric acid levels of 3-5 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Control</title>
            <description>The treatment arm will be compared to a standard of care arm.</description>
          </group>
        </group_list>
        <measure>
          <title>eGFR Change</title>
          <description>Change in Cys-C eGFR over time</description>
          <units>ml/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.14" spread="3.716"/>
                    <measurement group_id="O2" value="-0.29" spread="5.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1839</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>eGFR Change</title>
        <description>Change in Creatinine eGFR over time</description>
        <time_frame>The difference in Creatinine eGFR between baseline and 6 months will be measured</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol</title>
            <description>Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.&#xD;
Allopurinol: Allopurinol dosed to target uric acid levels of 3-5 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Control</title>
            <description>The treatment arm will be compared to a standard of care arm.</description>
          </group>
        </group_list>
        <measure>
          <title>eGFR Change</title>
          <description>Change in Creatinine eGFR over time</description>
          <units>ml/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" spread="7.798"/>
                    <measurement group_id="O2" value="0" spread="3.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3036</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Uric Acid Change</title>
        <description>Change in Serum Uric Acid</description>
        <time_frame>The difference in Serum Uric Acid between baseline and 6 months will be measured</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol</title>
            <description>Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.&#xD;
Allopurinol: Allopurinol dosed to target uric acid levels of 3-5 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Control</title>
            <description>The treatment arm will be compared to a standard of care arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Uric Acid Change</title>
          <description>Change in Serum Uric Acid</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.33" spread="0.996"/>
                    <measurement group_id="O2" value="-0.46" spread="0.964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <description>Change in systolic blood pressure</description>
        <time_frame>The difference in clinic systolic blood pressure between baseline and 6 months will be measured</time_frame>
        <population>Follow up blood pressure data was not collected from one participant in the treatment group</population>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol</title>
            <description>Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.&#xD;
Allopurinol: Allopurinol dosed to target uric acid levels of 3-5 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Control</title>
            <description>The treatment arm will be compared to a standard of care arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>Change in systolic blood pressure</description>
          <population>Follow up blood pressure data was not collected from one participant in the treatment group</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="13.126"/>
                    <measurement group_id="O2" value="2.29" spread="6.264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1421</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure</title>
        <description>Change in diastolic blood pressure</description>
        <time_frame>The difference in clinic diastolic blood pressure between baseline and 6 months will be measured</time_frame>
        <population>Follow up blood pressure data was not collected from one participant in the treatment group</population>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol</title>
            <description>Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.&#xD;
Allopurinol: Allopurinol dosed to target uric acid levels of 3-5 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Control</title>
            <description>The treatment arm will be compared to a standard of care arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <description>Change in diastolic blood pressure</description>
          <population>Follow up blood pressure data was not collected from one participant in the treatment group</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.33" spread="6.29"/>
                    <measurement group_id="O2" value="3.983" spread="7.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0022</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum High Sensitivity C-reactive Protein (Hs-CRP)</title>
        <description>Compare the mean difference of serum hs-CRP from baseline to 6 months between groups</description>
        <time_frame>Serum hs-CRP will be measured at baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol</title>
            <description>Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.&#xD;
Allopurinol: Allopurinol dosed to target uric acid levels of 3-5 mg/dL.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Control</title>
            <description>The treatment arm will be compared to a standard of care arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum High Sensitivity C-reactive Protein (Hs-CRP)</title>
          <description>Compare the mean difference of serum hs-CRP from baseline to 6 months between groups</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="3.724"/>
                    <measurement group_id="O2" value="-7.64" spread="18.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3032</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Interleukin 18</title>
        <description>Change in interleukin 18</description>
        <time_frame>Serum interleukin 18 will be measured at baseline, 3 months, and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Nlrp3</title>
        <description>Change in serum Nlrp3</description>
        <time_frame>Serum Nlrp3 will be measured at baseline, 3 months, and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Urine Neutrophil Gelatinase-associated Lipocalin (NGAL)</title>
        <description>Change in urine NGAL</description>
        <time_frame>Urine NGAL will be measured at baseline, 3 months, and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Urine Endothelin-1 (ET-1)</title>
        <description>Change in urine ET-1</description>
        <time_frame>Urine ET-1 will be measured at baseline, 3 months, and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Urine Kidney Injury Molecule-1 (KIM-1)</title>
        <description>Change in urine KIM-1</description>
        <time_frame>Urine KIM-1 will be measured at baseline, 3 months, and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Urine N-acetyl-Beta-D-Glucosaminidase (NAG)</title>
        <description>Change in urine NAG</description>
        <time_frame>Urine NAG will be measured at baseline, 3 months, and 6 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Regular investigator assessment, regular laboratory testing</desc>
      <group_list>
        <group group_id="E1">
          <title>Allopurinol</title>
          <description>Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.&#xD;
Allopurinol: Allopurinol dosed to target uric acid levels of 3-5 mg/dL.</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care Control</title>
          <description>The treatment arm will be compared to a standard of care arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome</sub_title>
                <description>Patient in treatment intervention developed DRESS syndrome directly attributable to Allopurinol. Required renal replacement therapy, prolonged steroid taper and has partially recovered.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cristin Kaspar, MD</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-628-3866</phone>
      <email>cristin.kaspar@vcuhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

